Moderna was recently told that the Health and Human Services Department (HHS) had withdrawn a $766million grant awarded by ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

We recently published a list of Jim Cramer Recently Discussed These 15 Stocks. In this article, we are going to take a look ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...

Jim Cramer recently endorsed Pfizer, excited by its cancer-fighting potential and robust drug pipeline. A caller praised ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...